ShaShares of Eli Lilly & Co. LLY,
they were down 5.2% in pre-sale trading on Monday, two days after the drugmaker said additional clinical trial data confirmed the potential role of its experimental Alzheimer’s disease drug in slow decline in people with early forms of the disease. The data were published in the New England Journal of Medicine Saturday, and examined results from a Phase 2 study that found that donanemab could reduce withdrawal by 32% compared to placebo at 76 weeks. Although the study met the main endpoint, the researchers reported that the secondary results from the experiment had mixed results. “If these findings are confirmed in the larger ongoing study, donanemab could offer the potential for disease-modifying treatment that helps patients with mental abilities and maintain their independence further, “Dr. Howard Fillit, chief science officer of the Alzheimer ‘s Drug Discovery Foundation, said in a statement. Lilly stock is up 49.3% over the past year, and the S&P 500 SPX more broadly,
has acquired 58.9%.